PDRN consists of purified DNA fragments derived from salmonid sources, a biological origin that has fueled social media trends. However, consumer interest is shifting: search data indicates that queries for the clinical name "PDRN" are rising, while interest in the sensationalist "salmon" framing is currently in decline. This suggests a market maturing toward ingredient-focused research rather than viral buzz.
Clinical evidence for topical application has historically been limited, but a 2026 study published in PLOS ONE provides early, albeit specific, data. In a 28-day trial, participants using a 0.1% PDRN eye cream showed a 20% to 23% reduction in crow’s-feet compared to 6% to 7% for retinol. While these results are promising, experts caution that this represents a single formulation. A separate 2026 systematic review of 183 participants noted potential in wound healing and skin rejuvenation but highlighted inconsistent protocols and small sample sizes as significant limitations.

Comments (0)
No comments yet. Be the first!